The Use of Antioxidants with First-Line Chemotherapy in Two Cases of Ovarian Cancer

@article{Drisko2003TheUO,
  title={The Use of Antioxidants with First-Line Chemotherapy in Two Cases of Ovarian Cancer},
  author={Jeanne A. Drisko and Julia A. Chapman and Verda J. Hunter},
  journal={Journal of the American College of Nutrition},
  year={2003},
  volume={22},
  pages={118 - 123}
}
OBJECTIVE Because of poor overall survival in advanced ovarian malignancies, patients often turn to alternative therapies despite controversy surrounding their use. [...] Key Result Both patients were optimally cytoreduced prior to first-line carboplatinum/paclitaxel chemotherapy. Patient 2 had a delay in initiation of chemotherapy secondary to co-morbid conditions and had evidence for progression of disease prior to institution of therapy. Patient 1 began oral high-dose antioxidant therapy during her first…Expand
Chemotherapy Alone vs. Chemotherapy Plus High Dose Multiple Antioxidants in Patients with Advanced Non Small Cell Lung Cancer
TLDR
The results do not support the concern that antioxidants might protect cancer cells from the free radical damage induced by chemotherapy, and larger trials are needed to demonstrate whether high-dose multiple antioxidants in conjunction with chemotherapy increase the response rates and/or survival time in advanced lung cancer. Expand
Continuous intravenous vitamin C in the cancer treatment: re-evaluation of a Phase I clinical study
TLDR
Continuous IVC infusions improved several parameters associated with poor cancer prognosis, and suggests a strategic benefit to using lower IVC doses in continuous infusions increased the frequency of side effects without noticeably increasing plasma ascorbate levels. Expand
High-Dose Parenteral Ascorbate Enhanced Chemosensitivity of Ovarian Cancer and Reduced Toxicity of Chemotherapy
TLDR
Investigation of the use of intravenous ascorbic acid in conjunction with chemotherapy for ovarian cancer, starting from preclinical models and culminating in a human trial, which demonstrated a significant reduction in chemotherapy-induced adverse effects in patients receiving asCorbate. Expand
Intravenous Vitamin C Therapy: A Natural Agent for Treating Cancer
TLDR
The rationale, safety, and efficacy of high-dose intravenous (IV) vitamin C as a natural chemotherapeutic agent is reviewed and concerns about using low-dose antioxidants with chemotherapy and radiation are raised. Expand
Multiple Dietary Antioxidants Enhance the Efficacy of Standard and Experimental Cancer Therapies and Decrease Their Toxicity
  • K. Prasad
  • Medicine
  • Integrative cancer therapies
  • 2004
TLDR
An active nutritional protocol that includes high doses of multiple dietary antioxidants and their derivatives, but not endogenously made antioxidants (glutathione- and antioxidant enzyme-elevating agents), when administered as an adjunct to radiation therapy, chemotherapy, or experimental therapy, may improve its efficacy by increasing tumor response and decreasing toxicity. Expand
Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer
TLDR
These initial safety data do not reveal increased toxicity with the addition of ascorbic acid to gemcitabine and erlotinib in pancreatic cancer patients, but the observed response to treatment suggests the need for a phase II study of longer duration. Expand
High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer
TLDR
An elaborate overview of pre-clinical and clinical studies using high-dose IVC as anti-cancer agent, as well as a detailed evaluation of the main known molecular mechanisms involved are provided. Expand
Cancer and Reduced Toxicity of Chemotherapy High-Dose Parenteral Ascorbate Enhanced Chemosensitivity of Ovarian
patients to tolerate higher (and potentially more effective) doses of chemotherapy. already make it a very valuable addition to chemotherapeutic regimens, because a reduction in toxicity would allowExpand
Intravenous Vitamin C and Cancer
TLDR
There is limited high-quality clinical evidence on the safety and effectiveness of IVC, but the existing evidence is suggestive of a good safety profile and potentially important antitumor activity; however, more rigorous evidence is needed to conclusively demonstrate these effects. Expand
Review of high‐dose intravenous vitamin C as an anticancer agent
TLDR
Current clinical evidence for a therapeutic effect of high‐dose IV vitamin C is ambiguous, being based on case series, and the interpretation and validation of these studies is hindered by limited correlation of plasma vitamin C concentrations with response. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 53 REFERENCES
Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial.
TLDR
The two groups showed no appreciable difference in changes in symptoms, performance status, appetite or weight, and were unable to show a therapeutic benefit of high-dose vitamin C treatment. Expand
Ovarian cancer update: management challenges and advances.
  • M. Markman
  • Medicine
  • Cleveland Clinic journal of medicine
  • 1994
TLDR
Because the patient's chance of survival is much better if the disease is discovered when it is still confined to the ovary, physicians should be alert to the possibility of ovarian cancer, particularly in postmenopausal women with vague abdominal complaints or with a palpable ovary. Expand
High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison.
TLDR
It can be concluded that high-dose vitamin C therapy is not effective against advanced malignant disease regardless of whether the patient has had any prior chemotherapy. Expand
Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer.
  • E. Cameron, L. Pauling
  • Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1976
TLDR
Analysis of the survival-time curves indicates that deaths occur for about 90% of the ascorbate-treated patients at one-third the rate for the controls and that the other 10% have a much greater survival time, averaging more than 20 times that for the Controls. Expand
Scientific Rationale for Using High-Dose Multiple Micronutrients as an Adjunct to Standard and Experimental Cancer Therapies
TLDR
It is hypothesized that high-dose multiple micronutrients, including antioxidants, as an adjunct to standard or experimental cancer therapy or experimental therapy, may improve the efficacy of cancer therapy by increasing tumor response and decreasing toxicity. Expand
The orthomolecular treatment of cancer. III. Reticulum cell sarcoma: double complete regression induced by high-dose ascorbic acid therapy.
TLDR
The response of a patient with histologically proven reticulum cell sarcoma to no treatment other than large doses of ascorbic acid is described and the significance of the therapeutic response is briefly discussed in relation to general schemes of cancer management. Expand
Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: A p53-independent induction of p21WAF1/CIP1 via C/EBPβ
TLDR
It is shown that the antioxidants pyrrolidinedithiocarbamate and vitamin E induce apoptosis in CRC Cells, and chemotherapeutic agents administered in the presence of antioxidants may provide a novel therapy for colorectal cancer. Expand
High doses of multiple antioxidant vitamins: essential ingredients in improving the efficacy of standard cancer therapy.
TLDR
This work proposes a working hypothesis that multiple antioxidant vitamin supplements together with diet and lifestyle modifications may improve the efficacy of standard and experimental cancer therapies. Expand
The orthomolecular treatment of cancer. I. The role of ascorbic acid in host resistance.
TLDR
The potential value of ascorbic acid in the supportive treatment of cancer is a matter for urgent study at many levels and offers the promise of general improvement in the results of cancer management. Expand
Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology.
TLDR
In most categories, CAM use was common among outpatients and given the number of patients combining vitamins and herbs with conventional treatments, the oncology community must improve patient-provider communication, offer reliable information to patients, and initiate research to determine possible drug-herb-vitamin interactions. Expand
...
1
2
3
4
5
...